Literature DB >> 10834274

Synthesis and antitumor activities of amino acid prodrugs of amino-combretastatins.

K Ohsumi1, T Hatanaka, R Nakagawa, Y Fukuda, Y Morinaga, Y Suga, Y Nihei, K Ohishi, Y Akiyama, T Tsuji.   

Abstract

The synthesis and antitumor activity of water-soluble amino acid prodrugs of amino-combretastatins were reported. Among the synthesized compounds, 7e (CS-39-L-Ser HCI, AC-7700) showed enhanced antitumor activity and decreased toxicity in a Colon 26 murine adenocarcinoma model. Compound 7e showed improved solubility and was easily formulated for in vivo administration. Compound 7e was cleaved to generate the parent compound, CS-39, in the whole blood of mice as well as man, possibly by the action of amino peptidase on the erythrocyte membrane.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10834274

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN： 0266-9536


  8 in total

1.  Synthesis and biological evaluation of indole-based, anti-cancer agents inspired by the vascular disrupting agent 2-(3'-hydroxy-4'-methoxyphenyl)-3-(3″,4″,5″-trimethoxybenzoyl)-6-methoxyindole (OXi8006).

Authors:  Matthew T Macdonough; Tracy E Strecker; Ernest Hamel; John J Hall; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney
Journal:  Bioorg Med Chem       Date:  2013-07-23       Impact factor: 3.641

Review 2.  Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds.

Authors:  Matthew M Cooney; Jose Ortiz; Ronald M Bukowski; Scot C Remick
Journal:  Curr Oncol Rep       Date:  2005-03       Impact factor: 5.075

3.  Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents.

Authors:  Laxman Devkota; Chen-Ming Lin; Tracy E Strecker; Yifan Wang; Justin K Tidmore; Zhi Chen; Rajsekhar Guddneppanavar; Christopher J Jelinek; Ramona Lopez; Li Liu; Ernest Hamel; Ralph P Mason; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney
Journal:  Bioorg Med Chem       Date:  2016-01-06       Impact factor: 3.641

4.  Structural interrogation of benzosuberene-based inhibitors of tubulin polymerization.

Authors:  Christine A Herdman; Laxman Devkota; Chen-Ming Lin; Haichan Niu; Tracy E Strecker; Ramona Lopez; Li Liu; Clinton S George; Rajendra P Tanpure; Ernest Hamel; David J Chaplin; Ralph P Mason; Mary Lynn Trawick; Kevin G Pinney
Journal:  Bioorg Med Chem       Date:  2015-12-15       Impact factor: 3.641

Review 5.  Tubulin-interactive natural products as anticancer agents.

Authors:  David G I Kingston
Journal:  J Nat Prod       Date:  2009-03-27       Impact factor: 4.050

6.  Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents.

Authors:  M V Ramana Reddy; Muralidhar R Mallireddigari; Venkat R Pallela; Stephen C Cosenza; Vinay K Billa; Balaiah Akula; D R C Venkata Subbaiah; E Vijaya Bharathi; Amol Padgaonkar; Hua Lv; James M Gallo; E Premkumar Reddy
Journal:  J Med Chem       Date:  2013-06-25       Impact factor: 7.446

7.  Synthesis of structurally diverse benzosuberene analogues and their biological evaluation as anti-cancer agents.

Authors:  Rajendra P Tanpure; Clinton S George; Tracy E Strecker; Laxman Devkota; Justin K Tidmore; Chen-Ming Lin; Christine A Herdman; Matthew T Macdonough; Madhavi Sriram; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney
Journal:  Bioorg Med Chem       Date:  2013-09-04       Impact factor: 3.641

8.  New (3-(1H-benzo[d]imidazol-2-yl))/(3-(3H-imidazo[4,5-b]pyridin-2-yl))-(1H-indol-5-yl)(3,4,5-trimethoxyphenyl)methanone conjugates as tubulin polymerization inhibitors.

Authors:  Kishore Mullagiri; V Lakshma Nayak; Satish Sunkari; Geeta Sai Mani; Sravanthi Devi Guggilapu; Burri Nagaraju; Abdullah Alarifi; Ahmed Kamal
Journal:  Medchemcomm       Date:  2017-12-12       Impact factor: 3.597
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.